Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis.
about
Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutationsThe effectiveness of EGFR-TKIs against brain metastases in EGFR mutation-positive non-small-cell lung cancer.Tyrosine kinase inhibitor combination therapy in first-line treatment of non-small-cell lung cancer: systematic review and network meta-analysis.Molecular pathways and therapeutic targets in lung cancerU.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations.Clinical utility of erlotinib for the treatment of non-small-cell lung cancer in Japanese patients: current evidenceImpact of EGFR mutation status on tumor response and progression free survival after first-line chemotherapy in patients with advanced non-small-cell lung cancer: a meta-analysisPooled analysis of clinical outcome for EGFR TKI-treated patients with EGFR mutation-positive NSCLCDifferent efficacy of EGFR tyrosine kinase inhibitors and prognosis in patients with subtypes of EGFR-mutated advanced non-small cell lung cancer: a meta-analysisRole of erlotinib in first-line and maintenance treatment of advanced non-small-cell lung cancer.Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer.Epithelial mesenchymal transition is required for acquisition of anoikis resistance and metastatic potential in adenoid cystic carcinomaDiffusion of molecular diagnostic lung cancer tests: a survey of german oncologistsRoles of EGFR and KRAS Mutations in the Treatment Of Patients With Non-Small-Cell Lung Cancer.AUY922 effectively overcomes MET- and AXL-mediated resistance to EGFR-TKI in lung cancer cellsPatients with exon 19 deletion were associated with longer progression-free survival compared to those with L858R mutation after first-line EGFR-TKIs for advanced non-small cell lung cancer: a meta-analysis.Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials.Autophagosome-mediated EGFR down-regulation induced by the CK2 inhibitor enhances the efficacy of EGFR-TKI on EGFR-mutant lung cancer cells with resistance by T790M.Treatment of nonsmall cell lung cancer: overcoming the resistance to epidermal growth factor receptor inhibitors.Radiotherapy for asymptomatic brain metastasis in epidermal growth factor receptor mutant non-small cell lung cancer without prior tyrosine kinase inhibitors treatment: a retrospective clinical studyEpidermal growth factor signals regulate dihydropyrimidine dehydrogenase expression in EGFR-mutated non-small-cell lung cancer.Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC.Comparison of molecular testing methods for the detection of EGFR mutations in formalin-fixed paraffin-embedded tissue specimens of non-small cell lung cancerMechanisms of resistance to reversible inhibitors of EGFR tyrosine kinase in non-small cell lung cancer.Targeted therapies in non-small cell lung carcinoma: what have we achieved so far?Local microwave ablation with continued EGFR tyrosine kinase inhibitor as a treatment strategy in advanced non-small cell lung cancers that developed extra-central nervous system oligoprogressive disease during EGFR tyrosine kinase inhibitor treatmeAre TKIs favourable for the elderly with non-small-cell lung cancer?How and when to use genetic markers for nonsmall cell lung cancer.Afatinib treatment in advanced non-small cell lung cancer.Mutations in the epidermal growth factor receptor gene in non-small cell lung cancer: Impact on treatment beyond gefitinib and erlotinib.Erlotinib: as maintenance monotherapy in non-small-cell lung cancer.Clinical outcomes with erlotinib in patients with epidermal growth factor receptor mutation.EGFR mutation status in brain metastases of non-small cell lung carcinoma.Erlotinib : a guide to its use in first-line treatment of non-small-cell lung cancer with epidermal growth factor-activating mutations.Clinical meta-analyses of targeted therapies in adenocarcinoma.Icotinib: activity and clinical application in Chinese patients with lung cancer.Personalized oncology: genomic screening in phase 1.Epidermal growth factor receptor (EGFR): A rising star in the era of precision medicine of lung cancer.EGFR tyrosine kinase mutation testing in the treatment of non-small-cell lung cancer.The LUX-Lung clinical trial program of afatinib for non-small-cell lung cancer.
P2860
Q21132357-8520B14F-733B-48B2-93AA-0A37B4E2D4A7Q33632386-67CDCFDD-233E-4DC0-967C-87EA5B6BA8E3Q33662730-601CE515-4BD5-4A4A-9655-54A71EF5182BQ33688872-D0311584-5299-424F-9CA8-C352E5E331F1Q33829794-7910C3DC-798F-4A73-8B87-FAF8A1F23837Q34011705-0AF1C389-FABC-46D0-8D56-86C3E2336D82Q34258399-05067F7D-595C-4623-A1ED-88927DBBF0E2Q34311186-05ED928A-D555-4F00-8A8D-0C52A1995257Q34333839-2C438031-399D-4412-9F72-820A3636021EQ34417886-86BD9925-A99D-4B00-A794-EF90D43A38F6Q34467915-9BA4ED53-D81B-4AB9-B3F3-94E04C7FC390Q34525327-FA29E2CB-75CF-4E0C-AC4D-E6D0D88761CDQ34608778-0A4DCA4A-3170-4FF6-BBA2-74CDD088BE2AQ35111284-C9574261-9F84-41CE-B015-C136E4D16B18Q35188254-102C2D34-3C44-4466-90DD-5C8C1AB316D9Q35252885-BBC15D03-4F0C-41AB-99E4-D6A96767C13AQ35345489-D6886C5E-416A-4722-828B-9FE93F533930Q35500311-6B131144-4A28-41C1-90EA-D0929FD16656Q35749960-416FCB69-ECD1-4E8B-AF9B-17584A941454Q35814752-C73B71D2-48A9-41B3-9126-3DFCA357F45CQ36042698-47B67C9F-782C-4675-A735-A4A444B633F0Q36673751-79CC5C66-BB3C-4076-8FB5-AA775CEB4F43Q36786024-75B630B7-F566-4EBD-961F-D9BCE02DFF07Q36942619-E0370C77-D346-4749-B9D6-95C1D87D75DDQ36999705-CC8FDB5E-5BE6-48F7-8533-0CDBF1AEB2B3Q37205228-988B6734-43CE-43E0-A41E-EEABF49ABCB9Q37564967-1E414BD7-3E49-4549-9E71-19BFDB0F7A34Q37588365-6026ED86-7AFC-413B-A60C-187802EA9957Q37645209-99D710D5-5C14-4672-A4B2-EC81C2D35D23Q37823422-FE3EA9CA-685B-4046-94A9-39247C8D160BQ37868006-D7D05CA5-B120-41BC-8B42-6DE348F7081AQ38019974-B34652C0-3C51-4799-AC14-E2933252EF54Q38053963-A2473AFC-7200-43CA-A80A-25D57142EA74Q38075484-39BC4354-333A-4DC5-833D-31A5A75667D5Q38077126-A87DF4AF-A91A-45FE-831F-A560B8698E04Q38192719-38CCCCEA-E015-4D90-90F7-347EAB1FBEEEQ38232150-221F0A8D-7100-4348-A0FF-05D74A48BE7CQ39254692-9A02C4DB-EEC1-426B-ABB9-CBCD9406CD71Q39362508-1555C0F6-0C52-4A84-A41B-3C401F9C7464Q39752575-C52D59C1-5077-4054-99A5-E56836F9FA34
P2860
Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 08 December 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Clinical outcomes in non-small ...... FR mutations: pooled analysis.
@en
Clinical outcomes in non-small ...... FR mutations: pooled analysis.
@nl
type
label
Clinical outcomes in non-small ...... FR mutations: pooled analysis.
@en
Clinical outcomes in non-small ...... FR mutations: pooled analysis.
@nl
prefLabel
Clinical outcomes in non-small ...... FR mutations: pooled analysis.
@en
Clinical outcomes in non-small ...... FR mutations: pooled analysis.
@nl
P2093
P2860
P921
P1476
Clinical outcomes in non-small ...... FR mutations: pooled analysis.
@en
P2093
Barbara Klughammer
Denis Soulières
Ivan Melezínek
Joachim Moecks
Lorenz Keil
Luis Paz-Ares
P2860
P356
10.1111/J.1582-4934.2009.00991.X
P577
2009-12-08T00:00:00Z
2010-01-01T00:00:00Z